Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 600 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 600 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $36.02, for a total value of $21,612.00. Following the completion of the transaction, the chief financial officer owned 88,240 shares of the company’s stock, valued at $3,178,404.80. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Stock Up 13.0%

Shares of NGNE stock opened at $36.80 on Wednesday. Neurogene Inc. has a 12-month low of $15.93 and a 12-month high of $37.27. The firm has a fifty day moving average of $29.70 and a 200-day moving average of $23.57. The company has a market capitalization of $581.44 million, a price-to-earnings ratio of -8.09 and a beta of 1.68.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, equities analysts expect that Neurogene Inc. will post -5.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Canaccord Genuity Group dropped their target price on Neurogene to $180.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. UBS Group set a $70.00 price target on shares of Neurogene in a research note on Wednesday, June 3rd. Rodman & Renshaw began coverage on shares of Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a research report on Tuesday, June 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Neurogene has an average rating of “Buy” and an average price target of $84.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NGNE. BNP Paribas Financial Markets increased its position in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Neurogene by 3.4% in the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after buying an additional 1,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after buying an additional 2,950 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in Neurogene during the fourth quarter worth $66,000. 52.37% of the stock is currently owned by institutional investors.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.